Diamyd Medical AB Class B DMYD_B

As European markets navigate renewed trade and geopolitical uncertainties, with the STOXX Europe 600 Index recently ending lower, investors are keenly observing growth opportunities within the region. In this context, companies with high insider ownership often attract attention for their potential alignment of interests between management and shareholders, making them compelling considerations in a fluctuating market environment.

Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, registrational Phase 3 DIAGNODE-3 trial in type 1 diabetes from 24 to 15 months, per FDA guidance, enabling the full primary efficacy readout of the trial to occur nine months earlier than previously planned and communicated. The previously announced interim efficacy readout, involving approximately 170 participants with 15-month data, remains o